Perspectives About Ascorbic Acid to Treat Inflammatory Bowel Diseases.
| Autor: | Andriolo IRL; Medicine Course, Health School - University of Itajai Valley, Itajai, SC, Brazil., Venzon L; Pharmaceutical Sciences Graduate Program - University of Itajai Valley, Itajai, SC, Brazil., da Silva LM; Department of Pharmacology, Federal University of Santa Catarina, Florianópolis, Santa Catarina, Brazil. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Drug research [Drug Res (Stuttg)] 2024 Apr; Vol. 74 (4), pp. 149-155. Date of Electronic Publication: 2024 Mar 11. |
| DOI: | 10.1055/a-2263-1388 |
| Abstrakt: | It is known that reactive oxygen species cause abnormal immune responses in the gut during inflammatory bowel diseases (IBD). Therefore, oxidative stress has been theorized as an agent of IBD development and antioxidant compounds such as vitamin C (L-ascorbic acid) have been studied as a new tool to treat IBD. Therefore, the potential of vitamin C to treat IBD was reviewed here as a critical discussion about this field and guide future research. Indeed, some preclinical studies have shown the beneficial effects of vitamin C in models of ulcerative colitis in mice and clinical and experimental findings have shown that deficiency in this vitamin is associated with the development of IBD and its worsening. The main mechanisms that may be involved in the activity of ascorbic acid in IBD include its well-established role as an antioxidant, but also others diversified actions. However, some experimental studies employed high doses of vitamin C and most of them did not perform dose-response curves and neither determined the minimum effective dose nor the ED Competing Interests: The authors declare that there is no conflict of interest. (Thieme. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|